Brief: Harpoon Therapeutics Announces Completion Of Planned Patient Enrollment In Early-Stage Blood Cancer Trial
27/06/2023 12:47
June 27 (Reuters) - Harpoon Therapeutics Inc HARP.O :
* HARPOON THERAPEUTICS ANNOUNCES COMPLETION OF PLANNED
PATIENT
ENROLLMENT IN PHASE 1 STUDY OF HPN217 IN RELAPSED/REFRACTORY
MULTIPLE MYELOMA
Source text for Eikon: ID:nGNXHZ5Dz
Further company coverage: HARP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Harpoon Therapeutics
See all newsBrief: Harpoon Therapeutics Receives 17 Additional Demands Seeking Disclosures in Proxy Statement
U.S. RESEARCH ROUNDUP-Axonics, BlackRock, Credit Acceptance
U.S. STOCKS ON THE MOVE-Core & Main, Commercial Metals, Equifax
U.S. STOCKS ON THE MOVE-Toll Brothers, American Eagle Outfitters, Twilio
Wrapup 1: Drugmakers kick off industry conference with two cancer deals